XML 52 R32.htm IDEA: XBRL DOCUMENT
v3.26.1

Basis of Presentation (Tables) | 12 Months Ended
--- | ---
Apr. 30, 2026
Investments accounted for using equity method [abstract] |
Summary of Subsidiaries which are Wholly Owned and Subject to Control | These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company:
Name of Subsidiary |  | % Equity Interest - April 30, 2026 |  | % Equity Interest - April 30, 2025, and 2024 |  | Country of Incorporation |  | Functional Currency
ImmunoPrecise Antibodies (Canada) Ltd. d/ba/ MindWalk Biologics |  | 100% |  | 100% |  | Canada |  | Canadian dollar
ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") |  | 100% |  | 100% |  | USA |  | U.S. dollar
ImmunoPrecise Antibodies (N.D.) LTD |  | 100% |  | 100% |  | USA |  | U.S. dollar
ImmunoPrecise Antibodies (MA) LLC |  | 100% |  | 100% |  | USA |  | U.S. dollar
Talem Therapeutics LLC ("Talem") |  | 100% |  | 100% |  | USA |  | U.S. dollar
ImmunoPrecise Netherlands B.V. |  | 100% |  | 100% |  | Netherlands |  | Euro
ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") |  | 0% |  | 100% |  | Netherlands |  | Euro
BioStrand B.V. d/b/a MindWalk |  | 100% |  | 100% |  | Belgium |  | Euro
Idea Family BV |  | 100% |  | 100% |  | Belgium |  | Euro
BioKey BV |  | 100% |  | 100% |  | Belgium |  | Euro
BioClue BV |  | 100% |  | 100% |  | Belgium |  | Euro
Summary of Discontinued Operations | The following table summarizes the major classes of line items included in income from discontinued operations, net of tax, as a result of the divestiture of IPA Europe and reclassification to discontinued operations:
|  |  |  |  |  |  |  | Year Ended April 30, |
(in thousands) |  | 2026 $ |  |  | 2025 $ |  |  | 2024 $ |
REVENUE |  |  | 4,737 |  |  |  | 13,894 |  |  |  | 14,239 |
COST OF SALES |  |  | 2,130 |  |  |  | 6,077 |  |  |  | 6,278 |
GROSS PROFIT |  |  | 2,607 |  |  |  | 7,817 |  |  |  | 7,961 |
EXPENSES |  |  |  |  |  |  |  |  |
Research and development |  |  | 125 |  |  |  | 643 |  |  |  | 304 |
Sales and marketing |  |  | 123 |  |  |  | 752 |  |  |  | 687 |
General and administrative |  |  | 832 |  |  |  | 2,658 |  |  |  | 2,952 |
Amortization of intangible assets |  |  | 109 |  |  |  | 418 |  |  |  | 602 |
|  |  | 1,189 |  |  |  | 4,471 |  |  |  | 4,545 |
Income before other income (expenses) and income taxes |  |  | 1,418 |  |  |  | 3,346 |  |  |  | 3,416 |
OTHER INCOME (EXPENSES) |  |  |  |  |  |  |  |  |
Grant income |  |  | 6 |  |  |  | 44 |  |  |  | 31 |
Interest, accretion and other income |  |  | — |  |  |  | 12 |  |  |  | 1 |
Unrealized foreign exchange gain (loss) |  |  | (4 | ) |  |  | (38 | ) |  |  | 10 |
|  |  | 2 |  |  |  | 18 |  |  |  | 42 |
Income before income taxes |  |  | 1,420 |  |  |  | 3,364 |  |  |  | 3,458 |
Income taxes |  |  | (267 | ) |  |  | (451 | ) |  |  | (272 | )
NET INCOME FROM DISCONTINUED OPERATIONS |  |  | 1,153 |  |  |  | 2,913 |  |  |  | 3,186 |
The following table summarizes the major classes of line items included in the statement of financial position as a result of the divestiture of IPA Europe and reclassification to discontinued operations on August 6,2025:
(in thousands) |  |
ASSETS |  |
Current assets |  |
Cash |  | 643 |
Amounts receivable, net |  | 3,071 |
Inventory |  | 1,665 |
Unbilled revenue |  | 646 |
Prepaid expense |  | 817 |
Deposit on equipment |  | 486 |
Property and equipment |  | 11,361 |
Intangible assets |  | 951 |
Goodwill |  | 8,297 |
Total assets |  | 27,937 |
LIABILITIES |  |
Current liabilities |  |
Accounts payable and accrued liabilities |  | 1,047 |
Deferred revenue |  | 723 |
Income taxes payable |  | 1,030 |
Leases |  | 9,429 |
Total liabilities |  | 12,229 |
Net assets included in discontinued operations |  | 15,708 |
Total liabilities and shareholders’ equity |  |

X
- Definition The disclosure of the analysis of the single amount of discontinued operations. [Refer: Discontinued operations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2025-01-01 -Paragraph 33 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 75 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph B4 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 75 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration